Breakthrough Alzheimer’s Medication Slows Disease Progression by a third
Experts Declare Imminent Availability of Alzheimer’s Drugs, Marking a Remarkable Shift from Previous Perceptions Donanemab, a drug developed by Eli Lilly, has demonstrated a significant 33% reduction in the progression of Alzheimer’s disease, prompting experts to describe the current stage as being “on the cusp” of groundbreaking treatments, an outcome that was deemed “impossible” not … Read more